Company research
Contineum Therapeutics, Inc.
CIK 1855175Updated Nov 9, 2026
SecurityCTNM · NASDAQ · equity
CTNM price & chart
Loading TradingView…
NASDAQ:CTNM on TradingView ↗About the company
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder. For more information, please visit www.contineum-tx.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
Bristol down as Street reacts to admilparant results in IPF ↗
J&J/Contineum depression candidate fails in phase 2 ↗
SEC disclosures
Contineum Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G/A - filed by Johnson & Johnson Innovation - JJDC, Inc. regarding Contineum Therapeutics, Inc.
SCHEDULE 13G - filed by FMR LLC regarding Contineum Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by FRANKLIN TEMPLETON INC regarding Contineum Therapeutics, Inc.
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 190,847,000Source | 216,034,000Source | 250,367,000Source | 182,888,000Source | 221,355,000Source | 261,349,000Source | 198,264,000Source | 123,564,000Source | 276,642,000Source | 212,847,000Source | 130,386,000Source |
| Property, Plant and Equipment, NetUSD | 880,000Source | 888,000Source | 929,000Source | 856,000Source | 801,000Source | 1,057,000Source | 891,000Source | 756,000Source | 830,000Source | 989,000Source | 678,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 42,633,000Source | 40,891,000Source | 14,711,000Source | 20,784,000Source | 77,230,000Source | 20,158,000Source | 22,470,000Source | 16,264,000Source | 75,603,000Source | 21,943,000Source | 15,526,000Source |
| Assets, CurrentUSD | 184,927,000Source | 215,143,000Source | 242,580,000Source | 176,839,000Source | 220,320,000Source | 252,964,000Source | 192,134,000Source | 119,711,000Source | 267,917,000Source | 206,388,000Source | 127,706,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,520,000Source | 1,232,000Source | 6,029,000Source | 1,355,000Source | 1,667,000Source | 6,636,000Source | 1,424,000Source | 1,804,000Source | 5,021,000Source | 1,628,000Source | 2,516,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,774,000Source | 5,600,000Source | 6,494,000Source | 5,007,000Source | 231,000Source | 7,016,000Source | 5,235,000Source | 474,000Source | 7,639,000Source | 5,467,000Source | 719,000Source |
| Other Assets, NoncurrentUSD | 266,000Source | 3,000Source | 364,000Source | 186,000Source | 3,000Source | 312,000Source | 4,000Source | 2,623,000Source | 256,000Source | 3,000Source | 1,283,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 10,377,000Source | 5,806,000Source | 10,707,000Source | 11,498,000Source | 3,852,000Source | 11,308,000Source | 13,496,000Source | 6,573,000Source | 15,653,000Source | 14,781,000Source | 5,702,000Source |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 342,400,000Source | 312,478,000Source | 447,185,000Source | 320,649,000Source | 310,174,000Source | 442,093,000Source | 317,964,000Source | 7,988,000Source | 438,072,000Source | 315,371,000Source | 7,098,000Source |
| Retained Earnings (Accumulated Deficit)USD | -162,224,000Source | -102,837,000Source | -206,990,000Source | -149,432,000Source | -92,570,000Source | -191,836,000Source | -133,392,000Source | -83,561,000Source | -177,380,000Source | -117,402,000Source | -75,144,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 265,000Source | 561,000Source | -573,000Source | 147,000Source | -127,000Source | -253,000Source | 170,000Source | -58,000Source | 260,000Source | 71,000Source | 108,000Source |
| Stockholders' Equity Attributable to ParentUSD | 180,470,000Source | 210,228,000Source | 239,660,000Source | 171,390,000Source | 217,503,000Source | 250,041,000Source | 184,768,000Source | -75,629,000Source | 260,989,000Source | 198,066,000Source | -67,936,000Source |
| Liabilities and EquityUSD | 190,847,000Source | 216,034,000Source | 250,367,000Source | 182,888,000Source | 221,355,000Source | 261,349,000Source | 198,264,000Source | 123,564,000Source | 276,642,000Source | 212,847,000Source | 130,386,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 6,361,000Source | 5,806,000Source | 6,526,000Source | 7,214,000Source | 3,739,000Source | 6,657,000Source | 8,949,000Source | 6,234,000Source | 9,744,000Source | 9,974,000Source | 5,484,000Source |
| Operating Lease, Liability, CurrentUSD | 1,477,000Source | 611,000Source | 2,393,000Source | 1,466,000Source | 484,000Source | 2,303,000Source | 1,455,000Source | 474,000Source | 2,341,000Source | 1,452,000Source | 464,000Source |
| Accounts Payable, CurrentUSD | 786,000Source | 1,397,000Source | 505,000Source | 2,001,000Source | 734,000Source | 1,495,000Source | 3,645,000Source | 570,000Source | 1,016,000Source | 1,811,000Source | 635,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,016,000Source | 0Source | 4,181,000Source | 4,284,000Source | 113,000Source | 4,651,000Source | 4,547,000Source | 111,000Source | 5,909,000Source | 4,807,000Source | 108,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | — | — | 0Source | — | — | 228,000Source | — | 0Source | 110,000Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | 4,098,000Source | 3,798,000Source | 3,628,000Source | 3,747,000Source | 2,521,000Source | 2,859,000Source | 3,849,000Source | 5,190,000Source | 6,387,000Source | 6,711,000Source | 4,385,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 182,400,000Source | 213,900,000Source | 236,600,000Source | 175,500,000Source | 218,700,000Source | 246,300,000Source | 190,700,000Source | 117,900,000Source | 262,900,000Source | 204,800,000Source | — |
| Common Stock, Value, Issued | — | — | — | — | — | — | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 83,000Source | 78,000Source | 323,000Source | 258,000Source | 195,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,823,000Source | 2,569,000Source | 10,038,000Source | 6,804,000Source | 2,219,000Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 490,000Source | 1,834,000Source | -869,000Source | 1,141,000Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -16,266,000Source | -14,412,000Source | -55,312,000Source | -32,845,000Source | 19,349,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -39,308,000Source | 14,915,000Source | -3,713,000Source | -69,739,000Source | -65,568,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 312,000Source | 47,000Source | 231,000Source | 514,000Source | 414,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 129,000Source | 24,000Source | 112,685,000Source | 109,001,000Source | 56,176,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,750,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -55,445,000Source | 527,000Source | 53,660,000Source | 6,417,000Source | 9,957,000Source |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 150,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,000Source | 0Source | 450,000Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,569,000Source | 2,291,000Source | 3,840,000Source | 2,418,000Source | 3,823,000Source | 2,569,000Source | 10,038,000Source | 200,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 0Source | -198,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 182,400,000Source | 213,900,000Source | 236,600,000Source | 175,500,000Source | 246,300,000Source | 190,700,000Source | 262,900,000Source | 204,800,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | 16,000Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 3,940,000Source | 3,246,000Source | 4,726,000Source | 3,839,000Source | 5,256,000Source | 4,398,000Source | 16,537,000Source | 12,472,000Source | 6,320,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 450,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 208,000Source |
| Investment Income, InterestUSD | — | — | 1,957,000Source | 2,741,000Source | 2,342,000Source | 2,029,000Source | 2,505,000Source | 2,250,000Source | 8,246,000Source | 8,905,000Source | 4,606,000Source |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | — | — | — | 0Source | 2,000Source | 12,000Source | 5,000Source | -19,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,792,000Source | -10,267,000Source | -15,154,000Source | -16,040,000Source | -14,456,000Source | -15,990,000Source | -59,978,000Source | -42,258,000Source | 22,720,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -12,792,000Source | -10,267,000Source | — | -16,040,000Source | — | -15,990,000Source | — | -42,258,000Source | 3,146,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,410,000Source | 2,707,000Source | 2,274,000Source | 1,862,000Source | 2,448,000Source | 2,120,000Source | 8,081,000Source | 8,636,000Source | 7,093,000Source |
| Operating ExpensesUSD | — | — | 14,932,000Source | 12,974,000Source | 17,428,000Source | 17,902,000Source | 16,904,000Source | 18,110,000Source | 68,059,000Source | 50,894,000Source | 33,923,000Source |
| Operating Lease, ExpenseUSD | — | — | 400,000Source | 300,000Source | 700,000Source | 400,000Source | 500,000Source | 400,000Source | 1,700,000Source | 1,100,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 183,000Source | -34,000Source | -68,000Source | -167,000Source | -57,000Source | -130,000Source | -165,000Source | -163,000Source | -177,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 108,211,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 198,000Source | 24,000Source | 219,000Source | 405,000Source | 159,000Source |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | — | —Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 50,000,000Source |
| Operating Income (Loss)USD | — | — | -14,932,000Source | -12,974,000Source | -17,428,000Source | -17,902,000Source | -16,904,000Source | -18,110,000Source | -68,059,000Source | -50,894,000Source | 16,077,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 183,000Source | -34,000Source | -68,000Source | -167,000Source | -57,000Source | -130,000Source | -165,000Source | -163,000Source | -177,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -10,267,000Source | — | — | — | — | -60,143,000Source | -42,258,000Source | 23,170,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 450,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,792,000Source | -10,267,000Source | -15,154,000Source | -16,040,000Source | -14,456,000Source | -15,990,000Source | -59,978,000Source | -42,258,000Source | 22,720,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.45Source | -0.4Source | -0.4Source | -0.62Source | -0.39Source | -0.62Source | -2.17Source | -2.18Source | 1.36Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.4Source | -0.4Source | -0.62Source | -0.39Source | -0.62Source | -2.17Source | -2.18Source | 0.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 28,115,548Source | 25,730,014Source | 37,467,840Source | 25,895,996Source | 37,339,026Source | 25,868,935Source | 27,700,855Source | 19,352,859Source | 2,308,972Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 25,730,014Source | 37,467,840Source | 25,895,996Source | 37,339,026Source | 25,868,935Source | 27,700,855Source | 19,352,859Source | 3,395,514Source |
| Interest Expense (non-operating)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | 208,000Source |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 3,940,000Source | 3,246,000Source | 4,726,000Source | 3,839,000Source | 5,256,000Source | 4,398,000Source | 16,537,000Source | 12,472,000Source | 6,320,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -60,143,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,957,000Source | 2,741,000Source | 2,342,000Source | 2,029,000Source | 2,505,000Source | 2,250,000Source | 8,246,000Source | 8,905,000Source | 4,606,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -12,792,000Source | -10,267,000Source | — | -16,040,000Source | — | -15,990,000Source | — | -42,258,000Source | 3,146,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,410,000Source | 2,707,000Source | 2,274,000Source | 1,862,000Source | 2,448,000Source | 2,120,000Source | 8,081,000Source | 8,636,000Source | 7,093,000Source |
| Operating ExpensesUSD | — | — | 14,932,000Source | 12,974,000Source | 17,428,000Source | 17,902,000Source | 16,904,000Source | 18,110,000Source | 68,059,000Source | 50,894,000Source | 33,923,000Source |
| Operating Lease, ExpenseUSD | — | — | 400,000Source | 300,000Source | 700,000Source | 400,000Source | 500,000Source | 400,000Source | 1,700,000Source | 1,100,000Source | — |
| Research and Development ExpenseUSD | — | — | 10,992,000Source | 9,728,000Source | 12,702,000Source | 14,063,000Source | 11,648,000Source | 13,712,000Source | 51,522,000Source | 38,422,000Source | 27,603,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 19,574,000Source |
Filing attachments
q3268kex991.htm · 8-K · 2026-11-03
Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS SAN DIEGO - November 3, 2026 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results. “Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fib…
Read attachment ↗q220268kex991.htm · 8-K · 2026-07-30
EX-99.1 2 q220268kex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO - July 30, 2026 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results an…
Read attachment ↗q120268kex991.htm · 8-K · 2026-05-05
EX-99.1 2 q120268kex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO - May 5, 2026 - Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2026 financial results and af…
Read attachment ↗a8-kpaindataex991.htm · 8-K · 2026-04-30
EX-99.1 2 a8-kpaindataex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ITS EXPLORATORY PIPE-791 PHASE 1B TRIAL IN CHRONIC PAIN - The trial achieved its primary endpoint demonstrating favorable safety and tolerability - Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported outcomes - Results support further evaluation of PIPE-791 for the p…
Read attachment ↗a2026_marchx8kxex991.htm · 8-K · 2026-03-05
EX-99.1 4 a2026_marchx8kxex991.htm EX-99.1 Document Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 SAN DIEGO - March 5, 202…
Read attachment ↗